Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder

Biological Psychiatry

Volumn 45, Issue 2, 1999, Pages 164-174

  Bergqvist, Peter B F ^a   Bouchard, Claude ^a   Blier, Pierre ^a  

^a Neurobiological Psychiat U M ^*  (Canada)

Author keywords

Autoreceptors; Electroconvulsive shocks; Fluoxetine; Heteroreceptors; Moclobemide; Orbitofrontal cortex

Indexed keywords

ANTIDEPRESSANT AGENT; AUTORECEPTOR; FLUOXETINE; MOCLOBEMIDE; PAROXETINE; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CINGULATE GYRUS; CLINICAL FEATURE; CONTROLLED STUDY; DESENSITIZATION; DORSAL RAPHE NUCLEUS; ELECTROCONVULSIVE THERAPY; HYPOTHALAMUS; LONG TERM EXPOSURE; MALE; MEDIAN RAPHE NUCLEUS; NEUROANATOMY; NONHUMAN; OBSESSION; ORBITAL CORTEX; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR SENSITIVITY; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZAMIDES; BRAIN; ELECTROCONVULSIVE THERAPY; FLUOXETINE; GUINEA PIGS; MALE; MOCLOBEMIDE; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN; TIME FACTORS;

EID: 0033556514     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(98)00154-1     Document Type: Article

References (50)

1. Baxter L.R. Jr, Phelps M.E., Mazziotta J.C., Guze B.H., Schwartz J.M., Selin C.E. Local cerebral glucose metabolic rates in obsessive-compulsive disorder A comparison with rates in unipolar depression and normal controls . Arch Gen Psychiatry. 44:1987;211-218.
2. Baxter L.R. Jr, Schwartz J.M., Mazziotta J.C., Phelps M.E., Pahl J.J., Guze B.H., et al. Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. Am J Psychiatry. 145:1988;1560-1563.
3. Baxter L.R. Jr, Schwartz J.M., Bergman K.S., Szuba M.P., Guze B.H., Mazziotta J.C., et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry. 49:1992;681-689.
4. Benkelfat C., Nordahl T.E., Semple W.E., King A.C., Murphy D.L., Cohen R.M. Local cerebral glucose metabolic rates in obsessive-compulsive disorder Patients treated with clomipramine . Arch Gen Psychiatry. 47:1990;840-848.
5. 3H]5-HT from the rat substantia nigra . Naunyn Schmiedebergs Arch Pharmacol. 335:1987;502-507.
6. Blier P., Bouchard C. Effect of repeated electroconvulsive shocks on serotonergic neurons. Eur J Pharmacol. 211:1992;365-373.
7. 3 receptor which modulates the release of 5-HT in the guinea-pig brain. Br J Pharmacol. 108:1993;13-22.
8. Blier P., Bouchard C. Modulation of 5-HT release in the guinea-pig brain following long-term administration of antidepressant drugs. Br J Pharmacol. 113:1994;485-495.
9. Blier P., Chaput Y., de Montigny C. Long-term 5-HT reuptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors An electrophysiological study in the rat brain . Naunyn Schmiedebergs Arch Pharmacol. 337:1988;246-254.
10. Blier P, Bergeron R, Piñeyro G, El Mansari M (in press): Understanding the mechanism of action of serotonin reuptake inhibitors in OCD: A step toward more effective treatments? In: Maser J, Goodman WK, editors. Treatment-Resistant Obsessive Compulsive Disorder.
11. Chaput Y., de Montigny C., Blier P. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors Electrophysiological studies in the rat brain . Naunyn Schmiedebergs Arch Pharmacol. 333:1986;342-348.
12. Chaput Y., de Montigny C., Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology. 5:1991;219-229.
13. Colzi A., D'Agostini F., Cesura A.M., Borroni E., Da Prada M. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus Evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo . J Pharmacol Exp Ther. 265:1993;103-111.
14. Consolazione A., Cuello A.C. CNS serotonin pathways. Osborne N.N. Biology of Serotonergic Transmission. 1982;29-61 Wiley, New York.
15. Da Prada M., Kettler R., Keller H.H., Burkard W.P., Muggli-Maniglio D., Haefely W.E. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther. 248:1989;400-414.
16. de Montigny C. Electroconvulsive shock treatments enhance responsiveness of forebrain neurons to serotonin. J Pharmacol Exp Ther. 228:1984;230-234.
17. Dolberg O.T., Iancu I., Sasson Y., Zohar J. The pathogenesis and treatment of obsessive-compulsive disorder. Clin Neuropharmacol. 19:1996;129-147.
18. El Mansari M., Bouchard C., Blier P. Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Relevance to treatment of obsessive-compulsive disorder. Neuropsychopharmacology. 13:1995;117-127.
19. Evans J.P.M., Grahame-Smith D.G., Green A.R., Tordoff A.F.C. Electroconvulsive shock increases the behavioural responses of rats to brain 5-hydroxytryptamine accumulation and central nervous system stimulant drugs. Br J Pharmacol. 56:1976;193-199.
20. 2 receptor-mediated regulation of serotonin extracellular concentration in the dorsal raphe nucleus of freely moving rats. J Neurochem. 61:1993;772-775.
21. Fineberg N.A., Bullock T., Montgomery D.B., Montgomery S.A. Serotonin reuptake inhibitors are the treatment of choice in obsessive compulsive disorder. Int Clin Psychopharmacol. 7:(suppl 1):1992;43-47.
22. Galzin A.M., Moret C., Verzier B., Langer S.Z. Interaction between tricyclic and nontricyclic 5-hydroxytryptamine uptake inhibitors and the presynaptic 5-hydroxytryptamine inhibitory autoreceptors in the rat hypothalamus. J Pharmacol Exp Ther. 235:1985;200-211.
23. Goodman W.K., Price L.H., Rasmussen S.A., Delgado P.L., Heninger G.R., Charney D.S. Efficacy of fluvoxamine in obsessive-compulsive disorder A double-blind comparison with placebo . Arch Gen Psychiatry. 46:1989;36-44.
24. Hoehn-Saric R., Pearlson G.D., Harris G.J., Machlin S.R., Camargo E.E. Effects of fluoxetine on regional cerebral blood flow in obsessive-compulsive patients. Am J Psychiatry. 148:1991;1243-1245.
25. Hoyer D., Middlemiss D.N. Species differences in the pharmacology of terminal 5-HT autoreceptor in mammalian brain. Trends Pharmacol Sci. 10:1989;130-132.
26. Insel T.R., Murphy D.L., Cohen R.M., Alterman I., Kilts C., Linnoila M. Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry. 40:1983;605-612.
27. Isberg R.S. A comparison of phenelzine and imipramine in an obsessive-compulsive patient. Am J Psychiatry. 138:1981;1250-1251.
28. Jain V.K., Swinson R.P., Thomas J.G. Phenelzine in obsessional neurosis. Br J Psychiatry. 117:1970;237-238.
29. Jenike M.A. MAOI for obsessive compulsive disorder. Br J Psychiatry. 140:1982;549.
30. Jenike M.A. Obsessive-compulsive disorder Efficacy of specific treatments as assessed by controlled trials . Psychopharmacol Bull. 29:1993;487-499.
31. Jenike M.A., Baer L., Minichiello W.E., Rauch S.L., Buttolph M.L. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry. 154:1997;1261-1264.
32. Joffe R.T., Swinson R.P. Tranylcypromine in primary obsessive-compulsive disorder. J Anxiety Disord. 4:1990;365-367.
33. Kalén P., Strecker R.E., Rosengren E., Björklund A. Regulation of striatal serotonin release by the lateral habenula-dorsal raphe pathway in the rat as demonstrated by in vivo microdialysis Role of excitatory amino acids and GABA . Brain Res. 492:1989;187-202.
34. Maletzky B., McFarland B., Burt A. Refractory obsessive compulsive disorder and ECT. Convuls Ther. 10:1994;34-42.
35. 2-adrenoceptors on serotonin terminals following long-term treatment with drugs increasing norepinephrine synaptic concentration. Neuropsychopharmacology. 10:1994;41-51.
36. Montgomery S.A., McIntyre A., Osterheider M., Sarteschi P., Zitterl W., Zohar J., et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur J Neuropsychopharmacol. 3:1993;143-152.
37. Moret C., Briley M. Serotonin autoreceptor subsensitivity and antidepressant activity. Eur J Pharmacol. 180:1990;351-356.
38. Nordahl T.E., Benkelfat C., Semple W.E., Gross M., King A.C., Cohen R.M. Cerebral glucose metabolic rates in obsessive compulsive disorder. Neuropsychopharmacology. 2:1989;23-28.
39. Park L.T., Jefferson J.W., Greist J.H. Obsessive-compulsive disorder. Treatment options. CNS Drugs. 7:1997;187-202.
40. 18F]FDG PET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment. Br J Psychiatry. 166:1995;244-250.
41. Piñeyro G., Blier P., Dennis T., de Montigny C. Desensitization of the neuronal 5-HT carrier following its long-term blockade. J Neurosci. 14:1994;3036-3047.
42. 1B knock-out mice. Neuroreport. 7:1995;353-359.
43. Rihmer Z., Szántó K., Arató M., Szabó M., Bagdy G. Response of phobic disorders with obsessive symptoms to MAO inhibitors. Am J Psychiatry. 139:1982;1374.
44. Swedo S.E., Schapiro M.B., Grady C.L., Cheslow D.L., Leonard H.L., Kumar A., et al. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Arch Gen Psychiatry. 46:1989;518-523.
45. Swedo S.E., Pietrini P., Leonard H.L., Schapiro M.B., Rettew D.C., Goldberger E.L., et al. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy. Arch Gen Psychiatry. 49:1992;690-694.
46. Tao R., Auerbach S.B. Differential effects of NMDA on extracellular serotonin in rat midbrain raphe and forebrain sites. J Neurochem. 66:1996;1067-1075.
47. Tollefson G.D., Rampey A.M., Potvin J.H. Jr, Jenike M.A., Rush A.J., Dominguez R.A., et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 51:1994;559-567.
48. Vallejo J., Olivares J., Marcos T., Bulbena A., Menchón J.M. Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial. Br J Psychiatry. 161:1992;665-670.
49. Yoshioka M., Matsumoto M., Togashi H., Smith C.B., Saito H. Opioid receptor regulation of 5-hydroxytryptamine release from the rat hippocampus measured by in vivo microdialysis. Brain Res. 613:1993;74-79.
50. Zohar J., Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry. 169:1996;468-474.